A phase II study of BIBW 2922, a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in patients with adenocarcinoma of the lung and activation EGFR mutations after failure of one line of chemotherapy (LUX-Lung2) - Shih,J.; Yang,C.; Su,W. (J Clin Oncol, 2009)